
NEW YORK, March 2 (UPI) -- Forest Laboratories said Thursday its patent on anti-depressant Lexapro has been extended for nearly two and a half years.
The company said it received a notice from the U.S. Patent and Trademark Office that its patent covering Lexapro's composition of matter has been extended for 828 days.
That means the Lexapro patent is now in effect until Sept. 14, 2011, and until March 14, 2012, with inclusion of six months' market exclusivity the drug maker was granted for completing pediatric studies of Lexapro.
Lexapro is currently approved to treat major depressive disorder and generalized anxiety disorder in adults.
Earlier this month reports said Forest Laboratories was substantially reducing its Lexapro inventories due to slumping U.S. sales. Forest is reportedly anticipating just under $2 billion in sales in fiscal 2006.
|
|
|
|
|
|
| Additional Health News Stories | |
MAYS LANDING, N.J., May 18 (UPI) --
A New Jersey woman was charged with murder Friday after police found her husband's body in a closet six years after he supposedly ran off with a girlfriend.
|
WASHINGTON, May 17 (UPI) --
James Taylor will headline a concert at the White House next week, when the Library of Congress honors Carole King with the Gershwin Prize for Popular Song.
|
CHICAGO, May 18 (UPI) --
Consulting firm Accenture said it would buy Chicago start-up marketing firm Acquity Group for $316 million or $13 per share, more than double its share value.
|
|
| Stories | Photos | Comments |
View Caption